Researchers identified KCTD10, a 'traffic controller' protein that shields DNA during cell division, potentially leading to new cancer therapies. The discovery could target cancer cells where DNA replication and transcription processes malfunction.
Mayo Clinic has been awarded up to $40 million by ARPA-H to develop new ways to monitor and improve air quality in real-time, enhancing patient care. The Hospital Air Quality (HAIQU) project will introduce cutting-edge biosensors, AI, and smart air filtration systems in emergency departments across Mayo's campuses.
A recent study published in Radiology found that adding molecular breast imaging to a 3D mammogram improved the ability to detect cancer in dense breast tissue. The combined test detected more cancerous tissue than either technique alone, increasing cancer finds by over double.
Mayo Clinic has opened its fifth international office in Dubai, providing patient support services and connecting patients with global healthcare resources. The new office offers assistance with travel, lodging, billing, and insurance arrangements, as well as facilitating communication between patients and healthcare providers.
Mayo Clinic's new program enables biopharma companies to accelerate clinical development by providing access to de-identified data, advanced AI tools, and a global distribution network. This collaboration streamlines access to Mayo Clinic's world-class research expertise, allowing companies to move efficiently from discovery to delivery.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
Saudi German Health has expanded its partnership with Mayo Clinic to become the largest group of Mayo Clinic Care Network members in the region. The partnership aims to enhance patient outcomes and quality of care through clinical transformation programs, sharing world-class expertise and resources.
Researchers at Mayo Clinic found that transplanting patients' own stem cells into their veins can help prevent inflammation and vein narrowing in patients with end-stage kidney disease. This could extend the time before dialysis is required, reducing healthcare costs and improving patient outcomes.
Researchers developed AI tools that use machine learning and natural language processing to extract details from doctors' notes. The tools detected a high-risk asthma subtype that makes some children more vulnerable to acute respiratory infections and asthma exacerbation.
Mayo Clinic researchers developed a genetic test that can predict how people will respond to weight loss medications. The test estimates an individual's calories to satiation, linking it to treatment success and providing personalized estimates of expected satiation threshold.
A new Mayo Clinic study found that many heart attacks in people under 65 are caused by factors other than clogged arteries, particularly in women. The study revealed that spontaneous coronary artery dissection (SCAD), embolism, and stress-related triggers accounted for over half of heart attacks in women under age 65.
A new genetic test developed at Mayo Clinic is redefining how clinicians diagnose and manage hereditary pancreatitis. The test includes nine genes and uses whole exome sequencing to analyze coding regions, providing comprehensive analysis of disease-causing genes.
Mayo Clinic researchers found that excessive alcohol alters an enzyme that recycles damaged proteins, leading to the accumulation of fat in liver cells. The study suggests that targeting this enzyme could prevent or treat fatty liver disease.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
A new study identifies a genetic biomarker, telomerase reverse transcriptase (TERT), that can predict the aggressiveness of meningiomas. High TERT expression is linked to faster disease progression and poorer outcomes, even in low-grade tumors.
A new Mayo Clinic AI tool, UNISOM, has shown promising results in identifying early signs of clonal hematopoiesis of indeterminate potential (CHIP), a condition that raises the risk of leukemia and heart disease. The tool helps detect CHIP-related mutations in standard genetic datasets, opening new avenues for research and discovery.
Researchers found specialized immune cells, called stem-like T cells, that behave like young stem cells but instead spread disease. These immune cells were found in over 100 older patients with autoimmune diseases, such as giant cell arteritis.
Researchers at Mayo Clinic have developed a new tool called BACDAC to identify signs of genomic instability in cancer. The tool uses DNA sequencing to detect structural alterations in tumors, which can fuel aggressive growth and evade standard testing.
Researchers identified a sugar molecule called sialic acid that helps cancer cells evade the immune system. By engineering beta cells to produce this molecule, they found it possible to tolerate these cells and prevent their destruction. The study offers new hope for treating type 1 diabetes without immunosuppression.
Mayo Clinic has been ranked as the top hospital in the US for 36 consecutive years, with two of its hospitals earning high scores in various specialties. The organization attributes its success to its commitment to innovation, excellence, and patient care.
Mayo Clinic has deployed NVIDIA Blackwell infrastructure to accelerate pathomics, drug discovery, and precision medicine using generative AI. The new infrastructure enables faster pathology slide analysis and foundation model development, reducing work time from four weeks to one week.
Researchers found that CAR-T cells age and lose effectiveness due to premature senescence, a previously unrecognized mechanism of therapy failure. The discovery highlights the need for next-generation therapies with improved durability.
A new AI model developed by Mayo Clinic and Ultromics can detect cardiac amyloidosis, a rare and progressive type of heart failure, with high accuracy. The model was validated on a large patient population and outperformed traditional screening methods in identifying the disease.
Researchers at Mayo Clinic developed pioneering therapies to prevent organ rejection without the need for immunosuppression. A recent phase 3 clinical trial found that 75% of participants were able to stop taking immunosuppressive medications for more than two years, with some patients staying off medication for over three years.
A Mayo Clinic team developed an AI system that can automatically identify surgical incisions and flag signs of infection in patient-submitted photos. The model achieved high accuracy in detecting incisions and identifying infections, with potential to streamline communication between patients and their care teams.
The Hospital Internacional de Colombia has joined the Mayo Clinic Care Network, a group of vetted health organizations with access to Mayo Clinic's knowledge and expertise. The network aims to advance high-quality patient-centered care through innovation and collaboration.
The AI tool, StateViewer, helps clinicians identify brain activity patterns linked to nine types of dementia, including Alzheimer's disease, using a single scan. It enables clinicians to interpret brain scans nearly twice as fast and with up to three times greater accuracy than standard workflows.
The Mayo Clinic in Arizona has launched a new lung transplant program, providing patients with end-stage lung disease a second chance at life. The program offers world-class care to critically ill patients battling respiratory diseases such as COPD, and is supported by clinical innovation from across Mayo Clinic.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
Mayo Clinic has opened its first carbon ion therapy program in the Western Hemisphere, providing new hope for patients with treatment-resistant cancers. The Duan Family Building will also offer advanced proton therapy and other cancer treatments.
Researchers validated a blood test for diagnosing Alzheimer's disease with 95% sensitivity and 82% specificity. The test measures two proteins associated with amyloid plaque buildup, offering a more accessible and cost-effective alternative to invasive PET scans.
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
The Mayo Venture Partner (MVP) program aims to create groundbreaking technologies, co-invest in aligned companies, and build new ventures from the ground up. Industry veterans will leverage Mayo Clinic's world-class research and clinical expertise to drive innovation.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
The new office staff will assist patients making appointments at Mayo Clinic in Minnesota, Arizona, Florida, and London, as well as help with travel arrangements and billing. The services are free of charge and include interpreter support for non-English speakers.
The Mayo Clinic has established the world's first biobank of human salivary gland tissue-organoids, which can help researchers find a cure for chronic dry mouth. The biobank contains specimens from 208 donors and has already identified biomarkers for mature, saliva-producing cells.
Researchers identified a biological process causing donor heart damage during cold storage and found that a drug can prevent this damage. Treatment with the drug nearly tripled pumping strength in human donor hearts, improving blood flow and reducing cell injury.
Mayo Clinic is expanding its patient information office in Guatemala City to provide more assistance to patients, including travel arrangements, billing, and insurance. The office staff will also facilitate coordination of care for patients visiting Mayo Clinic locations around the world.
A recent study published in the Journal of Hepatology has shown that simultaneous bariatric surgery and liver transplant is safe and improves long-term health outcomes for severely obese patients. The combined approach resulted in sustained weight loss, reduced risk of type 2 diabetes, and lower risk of fatty liver disease recurrence.
Researchers at Mayo Clinic developed AI-ECG tools that can detect heart muscle weakness in women of childbearing age, allowing for earlier identification and management. The tools demonstrated high diagnostic performance, with an area under the curve of .94 for AI-ECG and .98 for AI digital stethoscope.
Researchers at Mayo Clinic have identified a potential new way to monitor the progression of high-grade gliomas by developing a personalized blood test tailored to each patient's tumor DNA. The study suggests that this approach may provide a clearer picture of disease progression and enable clinicians to make more informed treatment de...
Researchers at Mayo Clinic discovered a rare genetic variant that can directly cause metabolic dysfunction-associated steatotic liver disease. The MET gene malfunction leads to fat accumulation, inflammation, and scarring, potentially progressing to cirrhosis or liver cancer.
Researchers found people with Tourette syndrome have 50% fewer interneurons, which calm excess movement signals, and stress responses in other brain cells. This deficit may contribute to the disorder's symptoms.
Researchers at Mayo Clinic developed a personalized deep brain stimulation platform to treat drug-resistant epilepsy. The study found that this approach reduced seizures while also improving memory and sleep in patients with temporal lobe epilepsy.
Researchers at Mayo Clinic are conducting a study to understand the factors that contribute to rapid progression of dementia in patients with Alzheimer's disease and Related Dementias. The team aims to identify biomarkers and disease-modifying targets that can improve diagnosis and treatment outcomes for these patients.
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
Mayo Clinic researchers have developed a new way to more precisely detect and monitor brain cell activity during deep brain stimulation, a common treatment for movement disorders. The study uses custom algorithms to record broadband signals associated with hand movement in patients undergoing awake DBS surgery.
Researchers identified fibronectin and smooth muscle actin as associated with resistance to immunotherapy treatment. Cancer-associated fibroblasts produce these proteins, which contribute to the suppression of the anti-tumor immune response.
Mayo Clinic is investing $1.9 billion in its Arizona campus, expanding clinical space by nearly 60% to care for more patients with complex medical conditions. The new facility will feature innovative care concepts, integrated technologies, and a better workplace for staff.
Mayo Clinic has been recognized as the world's best hospital for the seventh straight year by Newsweek, with a focus on delivering compassionate care to patients. The institution prioritizes innovation in clinical practice, education, and research to transform healthcare.